# Monomer Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/monomer-bio

- Industry: Biotechnology
- Headquarters: Pacifica, US
- Website: www.monomerbio.com/
- Total disclosed funding: $5.6M
- Latest round: Seed (Feb 1, 2024)
- Investors on record: 3

## About

Founded in 2021 by its CEO, Jimmy Sastra, and CTO, Mark Zhang, and based in California, US, Monomer Bio, Inc., operates as a life sciences company that provides lab automation solutions for biology companies. In January 2024, Monomer Bio, Inc., raised USD 5.6 million in seed funding led by Talis Capital, with participation from LifeX Ventures, Notley Ventures, and an individual investor.

The company offers automation solutions for cell culture processes, catering to various types of cells, including stem cells, primary cells, and immortalized cells.

Monomer's platform facilitates the gathering, structuring, and display of cultural data. Additionally, it allows integration with machine learning models to generate objective standards for cell health assessment and to identify potential issues such as contamination.

The company plans to use the January 2024 funding for expansion and to enhance its platform.

## Funding rounds

- Seed, Feb 1, 2024, $5.6M — Talis Capital, Notley Ventures, LifeX Ventures

## Investors

- Talis Capital (https://capitalatlas.ai/funds/talis-capital) — Seed
- Notley Ventures (https://capitalatlas.ai/funds/notley-ventures) — Seed
- LifeX Ventures (https://capitalatlas.ai/funds/lifex-ventures) — Seed